- ISIN
- IL0011429839
- CUSIP
- M40527109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 28, 2018
Highlights
- Market Cap
- $147.38M
- Enterprise Value
- $143.87M
- EPS (TTM)
- -$0.11
- Gross Profit (TTM)
- -$15.00K
- EBITDA (TTM)
- -$12.42M
- Year Range
- $0.91 - $4.20
- ROA (TTM)
- -40.88%
- ROE (TTM)
- -50.22%
- Avg. Volume (1M)
- 5M
- Avg. Volume Value (1M)
- $17.12M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ENTX Performance Chart
Entera Bio Ltd (ENTX) is up 54.1% since the beginning of the year. At $3 per share, ENTX is trading 28.8% below its 52-week high of $4. Investors who bought $1,000 worth of ENTX shares 5 years ago would now be looking at an investment worth $582.
Loading charts...
Compare this symbol against anything
Returns By Period
Entera Bio Ltd (ENTX) has returned 54.12% so far this year and 53.33% over the past 12 months.
Entera Bio Ltd
- 1D
- 1.36%
- 1M
- 80.12%
- 6M
- 118.25%
- YTD
- 54.12%
- 1Y
- 53.33%
- 3Y*
- 55.19%
- 5Y*
- -10.27%
- 10Y*
- —
- ALL TIME*
- -10.45%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ENTX Monthly Returns History
Based on dividend-adjusted daily data since Jun 28, 2018, ENTX's average daily return is +0.17%, while the average monthly return is +1.89%. At this rate, an investment would double in approximately 3.1 years.
Historically, 40% of months were positive and 60% were negative. The best month was Mar 2021 with a return of +129.5%, while the worst month was Dec 2018 at -42.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ENTX closed higher 42% of trading days. The best single day was Mar 11, 2021 with a return of +152.5%, while the worst single day was May 21, 2020 at -23.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -29.38% | 1.46% | -20.14% | 7.21% | 13.45% | 31.11% | 68.93% | 54.12% | |||||
| 2025 | 3.30% | -15.53% | -8.11% | 27.65% | -14.98% | 2.98% | 1.58% | -0.00% | -0.52% | 51.56% | -18.21% | -18.49% | -8.49% |
| 2024 | 40.07% | 63.61% | 21.45% | 17.37% | 14.80% | -18.22% | -12.50% | 3.73% | 13.77% | -4.74% | -9.39% | 29.27% | 253.33% |
| 2023 | 25.75% | -2.40% | 29.46% | -33.62% | 2.99% | 6.36% | -5.98% | -12.99% | 5.07% | -5.52% | 3.64% | -15.48% | -17.81% |
| 2022 | -18.65% | -6.99% | 34.74% | -14.63% | -12.24% | -38.14% | 45.86% | -30.41% | -22.96% | -24.75% | -13.26% | 7.54% | -74.07% |
| 2021 | 35.19% | 13.70% | 129.52% | -12.07% | -3.58% | 85.14% | -14.05% | -5.06% | -3.48% | -9.55% | -21.60% | -15.72% | 160.65% |
Benchmark Metrics
Entera Bio Ltd has an annualized alpha of 43.43%, beta of 0.49, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 28, 2018.
- This stock participated in 134.92% of S&P 500 Index downside but only 46.36% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.49 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 43.43%
- Beta
- 0.49
- R²
- 0.01
- Upside Capture
- 46.36%
- Downside Capture
- 134.92%
Return for Risk
Risk / Return Rank
ENTX ranks 67 for risk / return — above 67% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Entera Bio Ltd (ENTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ENTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.99 | ||
| Sortino ratioReturn per unit of downside risk | -0.03 | ||
| Omega ratioGain probability vs. loss probability | 1.21 | 1.25 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | 0.81 | 2.00 | -1.19 |
| Martin ratioReturn relative to average drawdown | 1.25 | 8.49 | -7.24 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Entera Bio Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Entera Bio Ltd was 93.15%, occurring on Nov 11, 2022. The portfolio has not yet recovered.
The current Entera Bio Ltd drawdown is 59.04%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-93.15%Nov 2022 | 4y 4mo | — | 8y 1moJun 2018 - now | Bear market2022 |
Drawdown Indicators
| ENTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.15% | -56.78% | -36.37% |
Max Drawdown (1Y)Largest decline over 1 year | -68.15% | -9.10% | -59.05% |
Max Drawdown (3Y)Largest decline over 3 years | -68.15% | -18.90% | -49.25% |
Max Drawdown (5Y)Largest decline over 5 years | -91.26% | -25.43% | -65.83% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -59.04% | -1.58% | -57.46% |
Average DrawdownAverage peak-to-trough decline | -68.20% | -10.70% | -57.50% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 44.00% | 2.14% | +41.86% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Entera Bio Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Entera Bio Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ENTX in comparison with other companies in the Biotechnology industry. Currently, ENTX has a P/B value of 13.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ENTX
Add Entera Bio Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ENTX